Eli Lilly and Company (NYSE: LLY) — The Best Drug Franchise of the Decade, Priced as if the Bull Case Already Happened

Report date: 2026-06-09 Price (as of 2026-06-09): $1,144.68 · Market cap: ~$1.02 trillion · Enterprise value: ~$1.06 trillion Shares outstanding: 891.7M · FY ends: December · Sector: Health Care / Pharmaceuticals · CIK: 0000059478

Other than the clearly-labeled “Claude’s Take” block below, the body of this article carries no buy/sell recommendation and no price target. It discusses valuation only as embedded expectations and scenarios.

⚡ Claude’s Take

This is the author’s own independent opinion and general information, not investment advice. The rest of this article remains recommendation-free and price-target-free.

Catchy tag: “The best drug franchise of the decade — priced like the bull case already happened.”

Verdict: HOLD / great business, demanding price — accumulate on weakness, not here. Conviction: medium-high on the business, medium on the stock.

Eli Lilly is the highest-quality large-cap pharmaceutical asset in the world right now, and it is not close. It owns the superior molecule in the largest new drug category in a generation (tirzepatide beats semaglutide head-to-head, ~20% vs ~14% weight loss in SURMOUNT-5), it is out-innovating a fading Novo Nordisk on the next two waves (oral orforglipron, now launched; triple-agonist retatrutide at ~28% weight loss), and the financials are extraordinary — 83% gross margins, ~49% operating margins, ~42% ROIC, revenue compounding from $34B (2023) to a guided $82–85B (2026). This is a genuine quality compounder with a real, if time-boxed, moat.

The problem is entirely the price. At ~$1,145 the stock carries a ~$1.06T enterprise value, ~41x trailing and ~26x forward earnings, and ~14x sales — roughly an 85% forward-P/E premium to large pharma. My reverse-DCF says the market is underwriting ~$140–160B of sustained terminal revenue at ~35% net margins (2.2–2.5x the 2025 base) — and, critically, that LLY still commands a ~20x+ multiple in 2030. The fragility is in that exit multiple, not the earnings: even a strong base case (~$56 EPS in 2030) de-rated to a normal 14–16x pharma multiple lands you near ~$900 — below today. So I am paying a premium price for a premium business at the precise moment three things turn into headwinds simultaneously: US net pricing is already eroding low-to-mid-teens under the MFN/IRA regime, the post-shortage supply tailwind is largely spent, and a flood of capital (LLY’s own $50B+ capex plus Novo, Amgen, Viking, Roche, and Chinese biosimilars) is entering the category — a textbook Marathon capital-cycle warning. The framing here is quality-compounder-at-a-full-price, not value and not deep-momentum; the margin of safety is thin.

What flips me bullish: real-world persistence/adherence data confirming GLP-1s are genuine chronic, lifetime-maintenance therapy (turning the TAM into an annuity), combined with net price stabilizing as volume offsets MFN cuts — at which point a pullback into the ~$850–950 zone (roughly 22–24x FY27 EPS) is a high-conviction accumulate. What flips me bearish: two-to-three consecutive quarters of net price falling faster than volume grows, or hard real-world data showing <40–50% 24-month adherence — either would break the annuity thesis the multiple depends on, and at this valuation there is no cushion to absorb it.

1. Executive Summary

Eli Lilly is, on the numbers, the standout franchise in global pharmaceuticals. Revenue has compounded from $28.3B (FY2021) to $65.2B (FY2025) — a +45% year in 2025 alone — and management has guided FY2026 to $82–85B (+28% at the midpoint) with non-GAAP EPS of $35.50–37.00. The engine is a single molecule, tirzepatide, sold as Mounjaro (type 2 diabetes, $23.0B in FY2025) and Zepbound (obesity, $13.5B). Together they were 56% of FY2025 revenue. Gross margin is ~83%, operating margin ~49%, ROIC ~42% — economics that improve, not deteriorate, with scale.

The investment question is not whether this is a good business — it plainly is — but whether the moat is durable enough, and the price reasonable enough, to underwrite a ~$1.02 trillion market capitalization. On the moat: LLY holds a stacked advantage — durable intangibles (composition-of-matter patents on tirzepatide to ~2036, best-in-class head-to-head clinical data, physician/brand trust, the deepest late-stage pipeline in pharma) layered on a powerful but depreciating manufacturing-scale advantage. In incretins, the binding constraint has been supply, not demand or efficacy, and LLY’s >$50B manufacturing build-out is a real barrier — but it is a barrier competitors are spending tens of billions to close.

On price: LLY trades at ~26x forward earnings, an ~85% premium to the large-pharma peer median (~14x), and ~14x sales. The premium is earned by ~55% revenue growth and elite margins, and on its own 10-year history the stock is mid-range (P/E in the 52nd percentile, having de-rated from >75x as earnings caught up). But the embedded expectations require LLY to land a ~15–18% revenue CAGR into a ~$140–160B, ~35%-net-margin annuity that survives the 2036 patent cliff — and to still command a premium multiple in 2030.

Three forces turn negative simultaneously over the medium term: (1) US net pricing is eroding low-to-mid-teens under the Inflation Reduction Act (IRA) and the November 2025 “Most Favored Nation” (MFN) / TrumpRx deal that prices GLP-1s at $245/month for Medicare; (2) the post-shortage supply-catch-up tailwind that flattered 2024–25 is essentially exhausted; and (3) capital is flooding the category (LLY, Novo, Amgen, Viking, Roche, Pfizer, Chinese biosimilars) — a classic Marathon capital-cycle warning. Offsetting these: a genuinely deep pipeline (oral orforglipron launched April 2026; retatrutide at ~28% weight loss), a barely-begun ex-US obesity runway, and new Medicare access from mid-2026.

Verdict orientation: a best-in-class business with a real-but-time-boxed moat, growing rapidly and allocating capital intelligently, whose equity already prices the successful execution of the bull case. The analysis that follows is recommendation-free; the judgment is reserved for Claude’s Take above.

2. Business Overview

What Lilly does. Eli Lilly and Company, founded 1876 and headquartered in Indianapolis, is a fully-integrated, research-driven pharmaceutical company that discovers, develops, manufactures, and markets patent-protected human medicines. It employs ~50,000 people and sells in the US, Europe, China, Japan, and internationally. Unlike a device or services business, Lilly’s entire economic value rests on molecules protected by patents and regulatory exclusivity — a temporary-monopoly business model in which the central tension is always the gap between today’s blockbuster and the patent cliff that ends it.

Lilly operates across four therapeutic areas:

• Cardiometabolic health (diabetes & obesity) — the dominant growth engine. Core assets: Mounjaro (tirzepatide) for type 2 diabetes; Zepbound (tirzepatide) for obesity; the legacy GLP-1 Trulicity (dulaglutide, now being cannibalized by tirzepatide); Jardiance (empagliflozin, SGLT2, partnered with Boehringer Ingelheim); and the legacy insulins (Humalog, Humulin, Basaglar). Orforglipron — an oral, small-molecule GLP-1 launched in April 2026 — is the newest cardiometabolic asset.
• Oncology — Verzenio (abemaciclib, CDK4/6 inhibitor for breast cancer, $5.7B in FY2025); Jaypirca (pirtobrutinib, BTK inhibitor); Cyramza, Retevmo, Erbitux, and the oral SERD Inluriyo. Much of this came via the 2019 Loxo Oncology acquisition.
• Immunology — Taltz (ixekizumab, IL-17 for psoriasis/PsA), Omvoh (mirikizumab, IL-23 for ulcerative colitis & Crohn’s), Ebglyss (lebrikizumab, IL-13 for atopic dermatitis), Olumiant (baricitinib, JAK).
• Neuroscience — Kisunla (donanemab, anti-amyloid for early Alzheimer’s, approved July 2024 and now the US amyloid-therapy share leader), Emgality (migraine).

How it makes money. Lilly sells branded prescription drugs to wholesalers, pharmacies, PBMs, hospitals, and — increasingly — directly to consumers through LillyDirect, a telehealth-and-pharmacy platform (>1M US patients; ~55% of new Zepbound starts are self-pay). Revenue is recognized on product sales net of rebates, discounts, and chargebacks — and the gap between gross (list) and net (realized) price is enormous and growing, a central theme of this memo. Revenue is recurring in the sense that chronic therapies generate repeat scripts, but it is not contractually locked: patients switch GLP-1s, adherence lapses, and formulary access shifts annually (LLY lost, then in May 2026 regained, CVS Caremark formulary position).

Revenue concentration (FY2025, from the 10-K). Of $65.2B total revenue, the incretin franchise (Mounjaro + Zepbound) was 56%; adding declining Trulicity pushes the incretin family toward ~60%. Geographically, the US was ~67% ($43.5B) and ex-US ~33% ($21.7B). Notably, Zepbound is almost entirely a US product today ($13.48B US vs just $58M ex-US) — obesity is largely pre-launch internationally, a major untapped runway. Mounjaro’s ex-US ramp ($9.3B) is further along.

Interpretation. This is, beneath a diversified-pharma surface, a single-franchise growth story. The two-year revenue trajectory ($34.1B → $45.0B → $65.2B) is overwhelmingly tirzepatide: Mounjaro nearly doubled (FY24 $11.5B → FY25 $23.0B) and Zepbound nearly tripled ($4.9B → $13.5B). The non-incretin base is real and diversifying — Verzenio at $5.7B, and fast-growing newer launches (Ebglyss, Omvoh, Jaypirca, Kisunla) — but small relative to the incretin tide. Management argues that “even without obesity, Lilly would be one of the fastest-growing pharma companies” (Q1 2026 call); that is plausible given the immunology/oncology/neuro book grew ~160% YoY in Q1 2026, but it grows off a base under ~15% of revenue, so it does not yet de-risk the concentration.

Verdict. A premier, R&D-driven pharmaceutical franchise with extraordinary current economics but high single-molecule concentration. The business is easy to understand at the top line (sell the best obesity/diabetes drug in a supply-starved mega-market) and genuinely diversifying underneath, but the thesis stands or falls on tirzepatide and its incretin successors.

3. Industry Dynamics

Structure. Large-cap branded pharma is, in the abstract, a structurally attractive industry: high gross margins (LLY ~83%), patent-conferred temporary monopolies, oligopolistic therapeutic categories, and very high regulatory barriers to entry (a new molecule costs ~$1–2B+ and a decade to bring through Phase III and FDA review). Within that, the anti-obesity-medication (AOM) / GLP-1 category is effectively a global duopoly — Eli Lilly and Novo Nordisk — with a handful of challengers years behind. The defining structural feature of the last three years has been that demand vastly exceeded the duopoly’s manufacturing supply, which suppressed normal price competition and let both players grow into a shortage. That is a temporary, not permanent, condition.

Market size. The obesity/GLP-1 TAM is genuinely enormous but the estimates are volatile, reflecting real uncertainty:

• Goldman Sachs: ~$114B global weight-loss drug market by 2030 (orals ~40% of that), revised up from prior ~$101B; Goldman has ranged $95–130B over time.
• Morgan Stanley: ~$105B by 2030 and ~$190B by 2035 for obesity + type 2 diabetes.

These forecasts rest on a load-bearing assumption — that GLP-1 therapy becomes durable chronic/lifetime use. Real-world discontinuation rates have been high (various datasets show ~50–70% discontinuation within a year), so the TAM is partly a bet that adherence improves as orals, lower prices, and broader reimbursement reduce friction. This is the single biggest swing factor for the entire industry.

Regulatory landscape — the central structural negative. US drug pricing policy turned materially against the category in 2025–26:

• IRA Medicare price negotiation. Lilly’s Jardiance was among the first 10 negotiated drugs, with the negotiated price effective January 1, 2026. Novo’s Ozempic/Wegovy are in the second tranche (effective 2027). Tirzepatide has not yet reached the negotiation-eligibility window (9 years for small molecules) but is a clear future target.
• MFN / “TrumpRx” deal (November 2025). Lilly and Novo agreed to offer Medicare GLP-1s (Ozempic/Wegovy/Mounjaro/Zepbound) at $245/month — below the IRA-negotiated $274 for Ozempic/Wegovy — plus a Medicare “Bridge” obesity-access program ($50/month copay) starting July 2026 and a voluntary Medicare obesity-coverage model from 2027. The oral GLP-1 list price was cut sharply via the direct-to-consumer TrumpRx channel (initial doses near $150–346/month vs a >$1,000 list). In exchange, Lilly secured a three-year tariff exemption and relief from certain future pricing mandates.

The net effect: US realized (net) prices are already falling. The 10-K and management commentary confirm US volume growth came with lower realized prices on Mounjaro/Zepbound, and FY2026 guidance bakes in low-to-mid-teens US price erosion. The bull case for the category must therefore come from volume, not price — government leverage plus the MFN precedent caps pricing upside structurally.

Capital-cycle read (Marathon lens). This is a textbook “capital rushing in” signal. Lilly alone has committed >$50B to manufacturing since 2020 (a $6.5B+ Texas API site, a Virginia site, Lebanon/Indiana, Concord/North Carolina, Wisconsin, plus Germany and Ireland), and Novo, Amgen, Roche, Viking, Pfizer, and Chinese players are all investing heavily. Marathon’s framework warns that abnormally high returns attracting heavy investment mean-revert: today the supply constraint protects pricing, but as the 2027–2029 capacity wave completes and orals/biosimilars arrive, the supply-side advantage that currently substitutes for pricing discipline erodes, and net prices likely compress faster.

Value chain & barriers. Barriers to entry are high (R&D, clinical trials, FDA approval, manufacturing scale, sales infrastructure) but barriers to competition within the category are lower than they look — patients switch molecules readily, and PBMs play Lilly against Novo annually on formulary placement (LLY’s 2024 CVS loss and 2026 win-back illustrate the lack of lock-in). Switching costs are weak; the moat is the molecule and the capacity, not customer captivity.

Verdict: structurally good today, structurally deteriorating over the medium term. The category is vast and under-supplied (favorable now), but it carries three durable negatives: (1) IRA + MFN government price compression, (2) a wave of capital and credible competitors entering, and (3) the patent-cliff endgame inherent to all pharma. Attractive while supply-constrained; a normalizing, more price-competitive oligopoly by the late 2020s.

4. Competitive Position

Naming the moat (Greenwald taxonomy). Lilly’s advantage is a stacked combination of two of Greenwald’s three genuine advantage types:

1. Intangibles — composition-of-matter and formulation patents, best-in-class clinical data, regulatory exclusivity, and physician/brand trust. This is the durable layer.
2. A temporary supply/cost-scale advantage in manufacturing — Lilly’s multi-year head start on peptide fill-finish and (for orforglipron) small-molecule capacity. This is the currently binding layer, but it is depreciating.

It is explicitly not a network-effects moat and only weakly a switching-cost moat — patients can and do switch GLP-1s, and formulary access turns over annually. The captivity that Greenwald prizes is largely absent; what protects Lilly is product superiority plus the physical inability of rivals to make enough drug fast enough.

The duopoly — Lilly vs Novo Nordisk. Within incretins, Lilly is the stronger of the two on every axis that matters:

• Clinical superiority (decisive). SURMOUNT-5, the first head-to-head trial (published 2025), showed tirzepatide (Zepbound) delivered −20.2% mean weight loss at 72 weeks vs −13.7% for semaglutide (Wegovy) — ~47% more weight loss (22.8 kg vs 15.0 kg). Mechanism: tirzepatide is a dual GIP/GLP-1 agonist vs semaglutide’s single GLP-1 pathway. This is not a marketing claim; it is a randomized head-to-head, and it is the foundation of Lilly’s share gains.
• Share. Lilly holds the larger and widening share of the US combined GLP-1 market (~60%) and, as of mid-2026, has overtaken Novo in ex-US GLP-1 share (>53% OUS per industry trackers). Novo, by contrast, is guiding to a sales decline in 2026 — the market is treating it as a fading share-loser (trailing P/E ~10–14x).

Manufacturing capacity as the real near-term moat. Today the binding constraint is not demand or efficacy — it is API and fill-finish capacity. Lilly’s >$50B build-out is a genuine scale/cost barrier: a new entrant cannot serve this market without billions in dedicated capacity and years of lead time. This is the strongest near-term moat. But it is a depreciating asset: a moat that consists of “we built capacity first” dissolves as everyone else’s capacity comes online (2027–2029) and as low-cost oral small molecules reduce the capacity intensity of serving the market.

The oral race — orforglipron. Lilly’s orforglipron (small-molecule, non-peptide oral GLP-1) was FDA-approved April 1, 2026 for chronic weight management (ATTAIN-1: −11.2% mean weight loss; highest dose ~12.4% at 72 weeks) and, critically, is taken with no food or water restrictions — a meaningful convenience edge over Novo’s oral semaglutide (which requires fasting and a 30-minute wait). As a small molecule it is far cheaper to manufacture at scale than injectable peptides, letting Lilly serve the ~40%-of-TAM oral segment without the peptide capacity bottleneck. The double edge: oral small molecules are also inherently easier to genericize and compound, which will accelerate eventual commoditization of the oral tier.

Pipeline as moat-extender — retatrutide. Retatrutide, a triple GIP/GLP-1/glucagon agonist, posted −28.3% weight loss at 80 weeks (and −30.3% at 104 weeks in high-BMI patients) in the TRIUMPH-1 Phase III trial reported June 2026 — approaching bariatric-surgery outcomes, with 60.6% reduction in sleep apnea events. This gives Lilly a next-generation efficacy leader to succeed tirzepatide and partially refresh the patent/efficacy moat ahead of the 2036 cliff. It is the clearest evidence that the durable moat is less “tirzepatide” and more “Lilly’s incretin R&D engine.”

Competitive threats. The duopoly will become a 4–6 player oligopoly by ~2028:

• Amgen MariTide — Phase III; ~20% weight loss at 52 weeks in Phase II; monthly dosing as a differentiator.
• Viking Therapeutics VK2735 — dual GIP/GLP-1; Phase II up to −14.7%; pivotal data late-2026/early-2027.
• Roche (CT-388), Pfizer, Boehringer (survodutide), Novo (CagriSema, amycretin) — all advancing.
• Chinese biosimilars and US compounders — pressure on price and especially the oral tier.

None of the challengers yet beats tirzepatide on published head-to-head efficacy, and retatrutide raises the bar further. But the number of credible entrants plus the capital flooding in is the clearest mean-reversion signal.

Patent cliff. Tirzepatide’s composition-of-matter patent expires January 2036 (~2037 with pediatric exclusivity), with formulation patents pushing generic launch toward ~2039. The core franchise thus has ~10 years of protected runway, after which biosimilar tirzepatide erodes it — the standard pharma endgame.

Pressure-testing the moat. What deteriorates without the moat? (1) When capacity catches up (2027–2029), the supply-scarcity premium that suppresses price competition disappears. (2) When orals commoditize, the cheaper-to-copy small molecule sees faster price decay. (3) When patents expire (2036–2039), tirzepatide goes biosimilar. The mitigant is the pipeline — retatrutide, orforglipron, eloralintide (amylin), plus oncology/immunology/neuro — which is the renewable part of the moat.

Verdict: a real but partially time-boxed moat. A stacked advantage — durable intangibles (patents to 2036/2039, best-in-class data, brand) over a powerful-but-depreciating manufacturing-scale lead. Lilly is the stronger half of the duopoly with the best molecule, the best next-gen asset, and a cost/convenience-advantaged oral. But this is a quality-compounder moat that must be continuously re-earned, not a permanent fortress. Highly durable through the early 2030s; durability beyond 2036 depends entirely on pipeline succession.

5. Growth History and Forward Opportunities

History. Revenue compounded $28.3B (FY21) → $28.5B (FY22) → $34.1B (FY23) → $45.0B (FY24) → $65.2B (FY25). The inflection is entirely tirzepatide. FY2025’s +45% was overwhelmingly volume: management “exceeded our goal to produce 1.8x the number of incretin doses in 2H’25 vs 2H’24.” Much of the 2024–25 growth was the unwinding of the tirzepatide shortage — supply catch-up, not pure demand creation — a crucial framing because that tailwind is now largely spent (management: “5 or 6 quarters deep into the post-shortage world,” Q1 2026). Q1 2026 revenue grew +56% YoY, with Mounjaro + Zepbound at $12.8B combined.

FY2026 guidance — raised at Q1. Management lifted guidance at the Q1 2026 call:

The ~$2B revenue / ~$2.00 EPS raise was driven by core Mounjaro/Zepbound demand, explicitly not by the new oral Foundayo (orforglipron) — a high-quality raise reflecting underlying product strength, not pipeline optionality.

Forward drivers (quantified where possible):

1. International incretin runway — the largest near-term leg. The total international incretin market grew +77% YoY (Q1 2026). Mounjaro is now launched in >55 countries with Lilly the OUS share leader (>53%). The tension management flags: in several markets share is already at US-Zepbound levels (~60% in Brazil/Korea), so “incremental share gain is getting harder; patient activation will be key.” OUS is ~75% out-of-pocket cash-pay weight management — durability of that cash-pay demand as generic semaglutide enters ex-US is an open question.
2. Oral orforglipron (“Foundayo”) — the scalability leg. Launched April 9, 2026. Early metrics: ~80% of prescriptions are “new to class,” >20,000 patients and >8,000 prescribers within ~3 weeks. A type 2 diabetes submission is expected late Q2 2026, with FDA action by year-end. Ex-US oral launches are mostly a 1H-2027 event. The thesis: oral expands the market (primary care, oral-preferring patients, ex-US/EM at low manufacturing cost) rather than cannibalizing injectables.
3. Medicare obesity access. The “Bridge” program ($50/month cap) starts by July 1, 2026 and runs through December 2027, opening millions of Part D-eligible patients. (Part D plans declined to opt into permanent 2027 coverage, so the government extended the Bridge — a mixed signal on durable Medicare coverage.)
4. Retatrutide and next-gen. TRIUMPH-1 (~28% weight loss) plus six further Phase III readouts in 2026; submissions for obesity, OSA, and knee osteoarthritis. Plus eloralintide (amylin, up to ~20% weight loss with best-in-class tolerability) and incretin-immunology combinations.
5. Indication expansion — sleep apnea (already approved for Zepbound), HFpEF, MASH, chronic kidney disease, osteoarthritis, and Alzheimer’s (Kisunla; preclinical-AD readouts ~2027) broaden the addressable population well beyond cosmetic weight loss.

Growth quality. High quality on the metrics that matter — organic (BD&L adds pipeline, not current revenue), volume-driven, increasingly diversified across four therapeutic areas, and self-funded at ~50% performance margins. The deepest late-stage pipeline in pharma (~40+ active Phase III programs) is the renewable engine. Two skeptic’s caveats, both of which management actively reframes: (1) US net price is eroding low-to-mid-teens — the Q1 2026 −7% headline was flattered by a one-time favorable rebate true-up; underlying was −10% — and the “volume far outstrips the price concession” elasticity claim is the unproven, load-bearing assumption; (2) the supply-catch-up tailwind is essentially exhausted, so future US growth must come from net-new demand, the oral, and Medicare, not from refilling a shortage.

Verdict: high-quality growth, with an asterisk on net pricing and a fading supply tailwind. Durable, organic, profitable, and diversified — but the next leg requires the volume-over-price bet and the international/oral/Medicare legs to deliver, in a category where the easy (shortage-driven) growth is behind it.

6. Financial Quality

Income statement. The operating leverage is now overwhelming.

FY2025 revenue +45% dropped to +95% net-income growth — the GLP-1 volume is absorbing a largely fixed cost base. Gross margin climbed 74% → 83% over five years; operating margin is ~49%. Q1 2026 net income rose +168% YoY (EPS $8.26 vs $3.06). R&D is falling as a percentage of sales (27.3% → 20.5%) only because revenue is outrunning it — absolute R&D nearly doubled to $13.3B, among the largest in pharma.

Cash flow and the capex ramp — the central capital fact.

PP&E spend rose 6x ($1.31B → $7.84B), running ~$9.3B annualized in Q1 2026; net PP&E on the balance sheet went from $9.0B (FY21) to $24.7B (FY25). FY2023 FCF cratered to $0.8B — the trough of the “spend ahead of revenue” phase, as a large working-capital drag hit OCF while capex climbed. FCF conversion has lagged net income every year because of the buildout: FY25 net income $20.6B vs FCF $9.0B. This is a deliberate, demand-driven investment phase, not a deterioration in earnings quality — but it does mean reported FCF understates the steady-state cash generation the business will throw off once the capacity is built and depreciating rather than under construction.

Balance sheet and leverage.

Net debt at FY25 ≈ $35.2B; net debt/EBITDA ≈ 1.0–1.1x — modest despite the buildout. Debt funded both capex and shareholder returns rather than crowding them out, though absolute debt has tripled since FY21 at higher rates. Inventory rose 3.5x ($3.9B → $14.5B) — the GLP-1 supply build, pre-positioning product and active ingredient ahead of demand. This is the single largest reversible asset on the balance sheet and the key quality-of-earnings watch item: if demand normalizes (oral cannibalization, Novo price competition, compounding leakage), this is the line that takes a write-down. So far it has been validated by sell-through.

Returns on capital. ROIC ≈ NOPAT ~$26B / invested capital ~$62B ≈ ~42% — genuinely elite and rising with scale. Reported ROE ~102–107% is real but partly a low-denominator artifact: chronic buybacks and immediate IPR&D write-offs suppress the equity base, inflating the ratio. ROIC is the cleaner read of the underlying economics, and it is excellent.

Quality of earnings — the IPR&D distortion (important). Lilly routinely expenses acquired in-process R&D immediately rather than capitalizing it: FY23 $3.8B, FY24 $3.28B, FY25 $2.91B. These are real cash BD&L deals expensed up front, depressing GAAP earnings — which is why FY2023 GAAP net income fell to $5.24B even as revenue grew 20% (a $3.8B IPR&D charge that year). The proxy confirms the gap: FY25 GAAP EPS $22.95 vs non-GAAP $24.21. For run-rate valuation, normalize IPR&D out and treat it as episodic deal spend. Net income is now converging up toward cash flow as IPR&D charges shrink and revenue scales (FY25 NI $20.6B vs OCF $16.8B — the inverse of the FY23 picture, the difference driven by the inventory build consuming cash).

Verdict: economics improve with scale, decisively. Gross margin 74% → 83%, operating margin ~49%, ROIC ~42%, with extraordinary incremental margins on incretin volume. The only caveats are self-inflicted timing (capex and inventory ahead of revenue) and IPR&D accounting noise — both obscure rather than impair the underlying economics. Accounting is conservative (IPR&D expensed, not capitalized); the watch items are the inventory build (reversible) and the gap between reported FCF and steady-state cash generation.

7. Capital Allocation

Dividends. DPS grew every year — $3.53 (FY21) → $6.23 (FY25), +76% over five years (~15% CAGR) — and the forward rate is $6.92 (~0.6% yield). Lilly has paid dividends since the 1880s and has a multi-decade increase streak. Payout is deliberately conservative (~22% of forward EPS) to fund the manufacturing buildout. Total dividends paid reached $5.38B in FY25.

Buybacks. Opportunistic, not the primary tool: cut to $750M in FY23 when capex and FCF were tight, then scaled to $4.1B in FY25 as cash flow recovered. This is rational, FCF-aware behavior (buy when affordable), though at LLY’s valuation buybacks are NPV-questionable — management appears to know this and keeps them secondary to capex.

Capex — the defining decision. The >$50B manufacturing build-out since 2020 (Lebanon IN, Concord NC, Wisconsin, plus Germany and Ireland) is the largest capital commitment in company history. Verified from filings: actual PP&E cash spend FY21–FY25 totaled ~$19.5B, with ~$9B+ annualized in 2026. The bet: incretin TAM is structurally under-supplied and being long capacity is the moat. The risk: these are 30-year fixed assets laid down against a demand curve that could compress if GLP-1 demand proves elastic to price/competition/oral-substitution. At current sell-through the bet is paying off — but it is the largest irreversible risk in the capital plan; these assets are not easily redeployable.

M&A / business development. Lilly has shifted from occasional mid-cap M&A to a high cadence of bolt-on, pipeline-deepening deals mostly expensed as IPR&D: Dice Therapeutics ($2.4B, 2023), Point Biopharma ($1.4B radioligand, 2023), Morphic Holdings ($3.2B, 2024), Scorpion Therapeutics (2025), Verve Therapeutics (2025), plus Centessa (orexin/sleep), Orna/Kelonia (in-vivo cell therapy), Ventyx (NLRP3), and others — ~39 deals in 2025. This is disciplined relative to mega-mergers; no franchise-betting acquisition. The watch item is the sheer cadence of clinical-stage BD (integration/execution risk, and the recurring IPR&D drag on GAAP EPS).

Executive compensation & alignment (2026 proxy). CEO David Ricks’s base salary is $1.7M (flat YoY); the FY25 bonus paid at 218% of target on strong performance. The annual bonus is three equally-weighted measures — product revenue (newer products), EPS, and pipeline progress; long-term awards are a Shareholder Value Award (absolute three-year stock-price growth) plus a Relative Value Award (TSR vs peer median, including Novo Nordisk). Metrics are well-aligned with growth, earnings, pipeline delivery, and relative TSR — though heavily stock-price-leveraged, which richly rewards the run-up. Robust stock-ownership guidelines, hedging/pledging prohibited, clawback in place; say-on-pay support >96%. Lilly Endowment Inc. (the charitable foundation) owns ~9.8%; Vanguard ~8.6%, BlackRock ~6.8%.

Insider signal. A sweep of the Form 4 corpus found zero code-P open-market purchases by any officer or director — all activity was routine grants (A), option exercises (M), tax withholding (F), and programmatic diversification selling by the Lilly Endowment. CEO Ricks’s activity was limited to routine grants/exercises. Read this as neutral (“nothing to see”), not a signal either way — insiders rarely buy at all-time highs, and the recurring sales are foundation diversification, not officer conviction.

Verdict: high-quality capital allocation, with one concentrated bet to watch. Disciplined dividend growth, opportunistic (non-dilutive) buybacks, bolt-on BD over empire-building, and reinvestment into a ~42% ROIC opportunity while keeping leverage ~1x — textbook intelligent allocation. The single risk is concentration: the 6x capex ramp and 3.5x inventory build are enormous and irreversible, wagered on durable GLP-1 demand.

8. Changes and Headwinds — Last Two Years

Headwinds to weigh. The structural negatives are (1) net price erosion under IRA/MFN (low-to-mid-teens in 2026 guidance); (2) the exhausted supply-catch-up tailwind; (3) intensifying competition (Amgen, Viking, Roche, Pfizer, Chinese biosimilars) compressing the duopoly toward an oligopoly by ~2028; (4) the heavy BD cadence raising integration risk; and (5) the manufacturing/inventory concentration. None is acute today, but together they describe a business whose easiest growth is behind it and whose pricing environment is structurally worsening.

Verdict: recent changes are net thesis-strengthening, the macro/pricing backdrop net-weakening. Product and pipeline news (Foundayo, retatrutide, CVS win-back, Kisunla, Medicare access) is overwhelmingly positive; the policy/pricing and competitive backdrop is the counterweight. On balance the franchise is stronger than two years ago, but the quality of the growth environment is deteriorating.

9. Risk Analysis (Risk Matrix)

The dominant risks are valuation-and-pricing (high likelihood, high impact) rather than business-quality risks. The business is excellent; the exposure is to the price paid and to the structural pricing/competition trajectory.

10. Valuation Discussion (Embedded Expectations)

No price target, no recommendation — embedded-expectations and scenario analysis only.

Where LLY sits versus peers.

(Yahoo Finance, 2026-06-09; NVO line items partially unreliable in the feed — anchored to secondary sources at ~10–14x trailing P/E.)

Quantifying the premium. LLY trades at the richest forward multiple in the group — ~25.7x vs a peer median ~13.9x, an ~85% forward-P/E premium — and at ~2–3x the group on EV/EBITDA (29x vs ~13.7x) and P/S (14x vs ~4.7x). Against Novo Nordisk, the only true comp, LLY trades at ~3–4x the trailing P/E. The peer group ex-LLY/NVO is mostly priced for patent-cliff stagnation (forward P/E 9–19x on 3–12% growth); LLY is in a different regime. The premium is explained by growth, not denied by it: LLY’s +55% revenue growth is ~5–10x the peer median with 83%/49% gross/operating margins and ~42% ROIC. PEG ~1.5 is the only multiple on which LLY looks merely “expensive-not-absurd.”

Crucially, Novo’s collapse to ~10–14x (guiding to a 2026 sales decline) shows the market will not reward a fading GLP-1 share-loser — so LLY’s premium is specifically a bet on durable share-gain plus pipeline, not on the category alone. On its own 10-year history, LLY is mid-range (P/E in the 52nd percentile, composite 62nd), having de-rated from >75x trailing a year ago to ~41x as earnings caught up to the price — i.e., expensive cross-sectionally but not versus itself.

Embedded expectations (reverse-DCF logic). At ~$1.06T EV, ~9% WACC, and ~3% terminal growth, the market needs roughly $48–55B of steady-state FCF capitalized (≈20x terminal FCF). At a ~33% FCF margin, that back-solves to ~$140–160B of terminal revenue — i.e., the market is underwriting LLY at ~2.2–2.5x its 2025 revenue base, reached and sustained. Bridging $65.2B (2025) to ~$150B by ~2030–2032 implies a ~15–18% revenue CAGR for 5–7 years, then deceleration to GDP-like terminal growth, with net margins expanding from ~32% toward ~35–38% on operating leverage. The current price is not pricing hyper-growth forever; it is pricing the successful landing of a high-teens grower into a high-margin annuity that survives the 2036 patent cliff on the strength of orforglipron, retatrutide, and ex-US expansion.

Scenario analysis (FY2030 target year; undiscounted value/share, ~870M shares).

What the market prices correctly vs aggressively. Correctly: the GLP-1 category is real, LLY’s molecule is superior, and duopoly economics are extraordinary while they last. Aggressively: the terminal multiple. The base case only “works” at ~$1,145 if LLY still earns a 22x exit P/E in 2030 — i.e., the market assumes LLY remains a premium-growth compounder four years out with no patent-cliff de-rate yet visible. If LLY de-rates toward a normal 14–16x large-pharma multiple as the 2036 LOE approaches, even strong base-case earnings (~$56 EPS) imply only ~$900 — below today. The valuation’s fragility is in the multiple, not the numerator.

Verdict orientation. LLY’s premium is earned by the growth and margins, and the stock is not expensive versus its own history. But the embedded expectations require a high-teens revenue CAGR and a sustained premium multiple through 2030 — a demanding combination that leaves little margin of safety if pricing, competition, or the multiple normalize even modestly.

11. Variant Perception

Consensus. The sell-side is decisively bullish (16 strong-buy / 7 buy / 4 hold / 2 sell; WS target ~$1,215). The consensus belief: LLY is the highest-quality large-cap pharma growth story in a generation — a $150B+ obesity/diabetes mega-TAM, LLY taking the larger and widening share, best-in-class molecules, and a pipeline (oral orforglipron, triple-agonist retatrutide) that extends the franchise past the 2036 cliff. Low beta (0.48), low short interest (0.88% of float) — this is not a contested name; it is a consensus quality long.

Strongest bull case. (a) TAM realization — obesity as a chronic, lifetime-use mega-category, with <10% of the eligible obese population currently treated. (b) Oral unlock — orforglipron removes injection/cold-chain friction, opening primary care and ex-US/EM volume at low manufacturing cost. © Pipeline optionality — retatrutide plus indications beyond weight (sleep apnea, MASH, CV, CKD, Alzheimer’s) that re-rate the TAM. (d) Pricing power within a duopoly as Novo fades. (e) Ex-US runway barely begun (Zepbound is ~$58M ex-US today).

Strongest bear case. (a) Pricing compression — MFN/IRA cut net prices structurally; net price could fall faster than volume grows. (b) Demand cyclicality / adherence cliff — if real-world GLP-1 use is churny rather than chronic, the annuity assumption breaks. © Competition compressing the duopoly — Amgen, Viking, Roche, Pfizer, and especially Chinese biosimilars post-2036; the “duopoly” is a 2026 snapshot, not a 2032 fact. (d) Manufacturing overbuild — a classic Marathon capital-cycle red flag as the industry pours $100B+ into obesity capacity, mean-reverting returns. (e) Patent cliff ~2036 plus no margin of safety — at 41x trailing / 14x sales, the price already discounts the bull landing.

The assumptions that matter most: (1) chronic-use durability (the biggest single swing factor); (2) net-pricing trajectory under MFN/IRA; (3) the terminal multiple (premium compounder vs normalized pharma); (4) share durability vs the next competitive wave; (5) capital-cycle discipline against $100B+ industry obesity capex.

Falsification tests. Falsifies the bull: real-world persistence data showing <40–50% 24-month adherence; a competitor matching tirzepatide efficacy at a lower price; net price declining faster than volume for 2–3 consecutive quarters; ex-US volume undershooting on affordability. Falsifies the bear: sustained net-price stability post-MFN with volume offsetting; orforglipron/retatrutide expanding rather than cannibalizing; adherence data confirming chronic use; LLY holding >55% combined share through the first wave of new entrants.

12. Fact vs. Interpretation Table

13. Open Questions

1. Adherence/persistence. What are the real-world 12- and 24-month adherence rates for tirzepatide specifically, and do orals/lower prices/Medicare access improve them enough to validate the chronic-use TAM?
2. Net-price trajectory. How fast does US net price erode through 2027–2029 as MFN/IRA annualize and capacity normalizes — and does volume genuinely “far outstrip” the price concession, as management claims?
3. Manufacturing utilization. Will the >$50B capacity be fully utilized, or is some of it stranded if demand proves elastic? What is the impairment risk on the $14.5B inventory if demand softens?
4. Terminal multiple. Does LLY hold a premium (~20x+) multiple as the 2036 LOE approaches, or de-rate toward normalized pharma — the single biggest driver of forward returns from here?
5. Pipeline succession. Do retatrutide and orforglipron fully offset the tirzepatide cliff and IRA exposure, or merely cushion it?
6. Ex-US cash-pay durability. How resilient is the ~75%-cash-pay OUS weight-management demand as generic semaglutide enters internationally?

14. What Must Be True

Bull case — what must be true:

• GLP-1 therapy proves durable, chronic, lifetime maintenance (not churny), turning the TAM into a real annuity.
• US net price stabilizes as volume offsets MFN/IRA cuts — the “volume far outstrips price” elasticity claim holds through a full price-down cycle.
• LLY holds >55% combined GLP-1 share through the first competitive wave (Amgen/Viking/Roche), and orforglipron + retatrutide expand rather than cannibalize the category.
• LLY retains a premium (~20x+) earnings multiple through 2030.
• Falsification test: two-to-three consecutive quarters of net price falling faster than volume grows, or real-world data showing <40–50% 24-month adherence, or a competitor matching tirzepatide efficacy at materially lower price.

Bear case — what must be true:

• Net price erodes faster than volume can offset under MFN/IRA, compressing the duopoly’s economics.
• Competition (Amgen, Viking, Chinese biosimilars) fragments share and triggers price competition as capacity normalizes (2027–2029).
• The ~$50B capex / $14.5B inventory bet proves partly stranded if demand is elastic.
• The multiple de-rates toward normalized large pharma (14–16x) ahead of the 2036 cliff, leaving even strong base-case earnings unsupportive of today’s price.
• Falsification test: sustained post-MFN net-price stability with volume offsetting, adherence data confirming chronic use, and LLY holding >55% share through the first competitive wave — which would validate the premium and break the bear.

15. Source Appendix

See the Source Appendix and Diligence Questionnaire below. Primary sources include: SEC EDGAR XBRL company facts (CIK 0000059478); LLY FY2025 Form 10-K and Q1 2026 Form 10-Q; LLY 2026 DEF 14A proxy; LLY Q4 2025 (Feb 4, 2026) and Q1 2026 (Apr 30, 2026) earnings-call transcripts; LLY press releases (FY2025 results / 2026 guidance, MFN/access agreement, orforglipron approval); SURMOUNT-5, ATTAIN-1, and TRIUMPH-1 clinical results; Goldman Sachs and Morgan Stanley obesity-market sizing; KFF on IRA negotiation; and yfinance/AZI market data (2026-06-09). Management commentary is treated as hypothesis and validated against filings and external evidence throughout.

Independent fundamental research. Recommendation-free and price-target-free except for the explicitly-labeled “Claude’s Take” block, which is the author’s own opinion and general information, not investment advice.

APPENDIX A — Standard Diligence Questionnaire

Eli Lilly and Company (NYSE: LLY) — as of 2026-06-09

Supplemental to the research memo. Fact / Interpretation / Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company? The recurring institutional debates: (1) Is GLP-1 use chronic/lifetime (annuity) or churny (high real-world discontinuation)? — the single biggest swing factor. (2) How fast does net price erode under IRA/MFN, and does volume genuinely offset it? (3) Is the >$50B manufacturing build-out prudent or an overbuild against elastic demand? (4) Does the premium multiple survive as the 2036 tirzepatide patent cliff approaches? (5) How durable is LLY’s share lead as Amgen/Viking/Roche/Chinese biosimilars arrive? (6) Is oral orforglipron market-expanding or injectable-cannibalizing?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Neither cyclical high nor low in the macro sense — LLY is in a secular growth phase, not a cycle. But the growth rate is arguably at a high: 2024–25 was flattered by post-shortage supply catch-up (now ~exhausted), and FY2026 net price carries a low-to-mid-teens headwind. Earnings are high-quality but the growth rate will likely decelerate from the +45–56% prints.

Driven by the external environment or internal actions? Predominantly internal — superior molecule (tirzepatide), manufacturing investment, pipeline execution. External tailwind (the shortage) is fading; external headwind (IRA/MFN pricing) is rising. The durable driver is internal R&D and capacity.

How stable are revenues? Fact/Interpretation: Recurring in the sense that chronic therapies generate repeat scripts, but not contractually locked — patients switch GLP-1s, adherence lapses, and PBM formulary access turns over annually (LLY lost CVS in 2024, regained it in 2026). Concentration (tirzepatide 56%) reduces diversification stability.

Outlook for products/services? Strong near-term (FY26 guided $82–85B, +28%), with three forward legs: ex-US incretin penetration, oral orforglipron, and Medicare obesity access. Medium-term tempered by pricing and competition.

How big will this market be? Fact (analyst): Global obesity/GLP-1 TAM ~$114B by 2030 (Goldman), ~$190B obesity+T2D by 2035 (Morgan Stanley). Growing, global, with ex-US and oral segments barely begun. Assumption: the size depends on chronic-use durability.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More. A 2026 duopoly (LLY/Novo) becomes a 4–6 player oligopoly by ~2028 (Amgen MariTide, Viking, Roche, Pfizer, Chinese biosimilars), plus a flood of capital — a Marathon capital-cycle warning.

How profitable is the business (ROIC, ROE)? Fact: ROIC ~42% (elite, rising with scale); ROE ~102–107% (real but inflated by a thin equity base from buybacks + immediate IPR&D write-offs). Gross margin 83%, operating margin ~49%.

How profitable is the industry — competitors, barriers? Large-cap branded pharma is high-margin and high-barrier (R&D, trials, FDA, manufacturing scale). Barriers to entry are high; barriers to competition within the GLP-1 category are lower (patients switch, PBMs play players off each other). The current super-profitability is supply-constraint-driven and will compress.

Can the business be easily understood? Yes at the top line (sell the best obesity/diabetes drug in a supply-starved mega-market); the complexity is in pricing (gross-to-net), pipeline probability, and patent timing.

Undermined by foreign low-cost labor? Not labor — but Chinese biosimilars are a real post-patent threat to price, and low-cost small-molecule manufacturing makes the oral tier more genericizable.

Do brands matter? Yes — Mounjaro/Zepbound brand equity, physician trust, and LillyDirect’s direct consumer relationship matter, but brand does not prevent molecule-switching the way it locks in a consumer staple.

Nature of competition? Clinical efficacy (head-to-head data), manufacturing capacity, formulary access/price, and pipeline succession. Currently efficacy + capacity favor LLY decisively.

Customers’ switching costs? Low. Patients switch GLP-1s; formulary access shifts annually. The moat is product superiority and supply, not switching costs.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Interpretation: Yes — the pipeline and brand value of internally-developed and IPR&D-expensed assets are not capitalized (LLY expenses acquired IPR&D immediately: $2.9–3.8B/yr FY23–25). This understates book value and inflates ROE. The deepest Phase III pipeline in pharma carries large unrecognized option value.

Off-balance-sheet liabilities? Standard pharma exposures: product-liability/litigation contingencies, milestone/royalty obligations from BD&L deals, and operating commitments. No unusual off-balance-sheet leverage flagged.

How conservative is the accounting? Conservative. IPR&D expensed not capitalized (depresses GAAP EPS — FY25 GAAP $22.95 vs non-GAAP $24.21); revenue recognized net of rebates. The main quality-of-earnings watch item is the $14.5B inventory build (reversible if demand softens), not aggressive recognition.

How CapEx-hungry is the business? Currently very — capex rose 6x to $7.84B (FY25), ~$9.3B annualized in 2026, as part of the >$50B manufacturing build-out. This is a deliberate, demand-driven phase; steady-state capex intensity should normalize once capacity is built, lifting FCF conversion.

Capital Allocation & Management

How much FCF, and how is it used? Fact: FY25 FCF ~$9.0B (OCF $16.8B − capex $7.84B) — depressed by the buildout vs $20.6B net income. Uses: capex first (highest-ROIC opportunity), then growing dividend ($5.38B FY25), then opportunistic buybacks ($4.1B FY25) and bolt-on BD&L. Philosophy: reinvest into the franchise while maintaining a conservative ~22% dividend payout.

Significant acquisitions recently? Fact: High cadence of bolt-on deals — Dice ($2.4B), Point Biopharma ($1.4B), Morphic ($3.2B), Scorpion, Verve, Centessa, Orna/Kelonia, Ventyx; ~39 deals in 2025. Disciplined (no mega-merger); watch item is integration/execution risk and recurring IPR&D drag.

Buying back shares? Yes, opportunistically ($0.75B FY23 → $4.1B FY25) — secondary to capex; NPV-questionable at this valuation, and management keeps it subordinate.

Issuing large amounts of stock to insiders? No unusual dilution; routine equity comp. Share count is roughly flat-to-declining net of buybacks.

Compensation policy. Fact: CEO base $1.7M; annual bonus = product revenue + EPS + pipeline (equal weight); long-term = absolute 3-yr stock-price (SVA) + relative TSR (RVA, incl. Novo). Well-aligned, heavily stock-price-leveraged; say-on-pay >96%; hedging/pledging prohibited; clawback in place.

Motivations of management. Aligned with shareholders via large equity-linked comp and ownership guidelines; Lilly Endowment owns ~9.8%. No evidence of empire-building or self-dealing; capital allocation is disciplined.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — LLY is a US C-corp common stock, NYSE-listed; standard 1099 dividend treatment. (Novo Nordisk, the key comp, is an ADR.)

Dividend policy? Conservative and steadily growing — forward $6.92 (~0.6% yield), ~22% payout, multi-decade increase streak; dividends paid since the 1880s.

How profitable? Extraordinarily — 83% gross, ~49% operating, ~35% net margin, ~42% ROIC.

Net income vs cash from operations? Fact: FY25 NI $20.6B > OCF $16.8B — the gap is the inventory build consuming cash (the inverse of FY23, when a $3.8B IPR&D charge depressed NI below OCF). Watch the inventory line as the key reconciliation item; not a red flag at current sell-through.

Risks & Downside

What would cause the stock to decline? Net price eroding faster than volume; a competitor matching tirzepatide efficacy at lower price; weak real-world adherence data breaking the chronic-use thesis; a multiple de-rate toward normalized pharma; a GLP-1 class safety signal; manufacturing/inventory impairment.

Risk of catastrophic loss? Low. A diversified, profitable, investment-grade large-cap pharma (net debt/EBITDA ~1x). The realistic downside is multiple compression + slower growth (the bear scenario implies ~−54% to FY30 value, ~$525), not insolvency.

Chance of total loss? Negligible. Strong balance sheet, broad product base, deep pipeline. The risk is valuation (overpaying for a great business), not permanent capital impairment from a solvency event.

Recent News & Events

Has the business environment changed recently? Yes — three material 2025–26 shifts: (1) the MFN/TrumpRx pricing deal ($245 Medicare GLP-1 pricing, oral list cut, but tariff/policy relief and Medicare access unlocked); (2) orforglipron FDA approval (April 2026) launching the oral leg; (3) the CVS Caremark formulary win-back (May 2026) reversing the 2024 Novo exclusivity loss. Plus the retatrutide TRIUMPH-1 readout (~28% weight loss, June 2026).

Significant acquisitions? Continuous bolt-on BD&L (see above); no transformational M&A.

Change in accounting policies? None material; IPR&D continues to be expensed (a long-standing conservative policy).

Recent changes — markets, facilities, management? Major manufacturing expansion (US, Germany, Ireland); LillyDirect direct-to-consumer scale-up (>1M patients); ex-US incretin launches (>55 countries); stable management (CEO David Ricks). No leadership instability or governance disruption.

APPENDIX B — Source Appendix

Eli Lilly and Company (NYSE: LLY) — as of 2026-06-09

Sources are primary-first. Management commentary is treated as hypothesis and validated against filings and external evidence. All accessed 2026-06-09 unless noted.

Primary — SEC filings & regulatory (CIK 0000059478)

Primary — Clinical & company disclosures

Secondary — market sizing, competition, market data

Data integrity notes: (1) Financial statement detail is from SEC EDGAR XBRL and the 10-K/10-Q (authoritative). (2) Some third-party peer-comp feeds returned implausible Novo Nordisk EV/EBITDA and P/S line items; NVO multiples were anchored to secondary sources. (3) Non-GAAP figures (performance margin, non-GAAP EPS) are management-defined and reconciled to GAAP in LLY’s releases; IPR&D charges were normalized out for run-rate discussion. (4) The >$50B manufacturing figure is a company multi-year commitment claim, not a single XBRL line; verified PP&E cash spend FY21–FY25 was ~$19.5B.